Video
Dr. Rapoport on Rolapitant for the Prevention of CINV
Author(s):
Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).
Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).
This phase III trial, of which the results were presented at the 2014 MASCC/ISOO International Symposium, analyzed 555 cisplatin-naïve subjects treated with highly emetogenic chemotherapy (≥60mg/m2 cisplatin). Patients were randomized to receive rolapitant, granisetron, and dexamethasone, or placebo, granisetron, and dexamethasone.
Rolapitant is different from other NK-1 inhibitors in that it does not interaction with any other drug and has a long half-life.
In this trial, rolapitant demonstrated superior efficacy in the primary endpoint of delayed CINV in this population.
